Skip to main content

SYSTEMATIC REVIEW article

Front. Surg.
Sec. Thoracic Surgery
Volume 11 - 2024 | doi: 10.3389/fsurg.2024.1500593

Prognosis prediction using significant pathological response following neoadjuvant immunotherapy in resectable non-small-cell lung tumors: A metaanalysis

Provisionally accepted
Fang Nie Fang Nie Ying Wang Ying Wang Wanting Shi Wanting Shi Liru Zhu Liru Zhu Jing Hao Jing Hao Rancen Tao Rancen Tao *
  • Department of Oncology, Inner Mongolia Autonomous Region Cancer Hospital, Hohhot, China

The final, formatted version of the article will be published soon.

    A meta-analysis study was done to figure out how to predict the prognosis of people with resectable non-small-cell lung cancer (NSCLC) who had a significant pathological response following neoadjuvant immunotherapy.Up until August 2024, a comprehensive literature study was completed, and 2386 connected studies were revised. The 35 selected studies included 3118 resectable nonsmall-cell lung tumor participants at the beginning of the study. Using dichotomous techniques and a fixed or random model, the odds ratio (OR) and 95% confidence intervals (CIs) were used to assess the prediction using significant pathological response following neoadjuvant immunotherapy in resectable NSCLC.Individuals with resectable NSCLC had significantly higher major pathological response when comparing neoadjuvant chemo-immunotherapy to neoadjuvant chemotherapy (OR, 5.07; 95% CI, 4.09-6.27, p<0.001), objective response rate to non-objective response rate (OR, 7.02; 95% CI, 4.28-11.50, p<0.001), and programmed death-ligand 1≥1% to programmed death-ligand ≤1% (OR, 2.49; 95% CI, 1.44-4.30, p=0.001).However, no significant difference was found in major pathological response between stage III and stage I-II (OR, 1.43; 95% CI, 0.88-2.33, p = 0.15), and squamous cell cancer and non-squamous cell cancer (OR, 1.35; 95% CI, 0.95-1.92, p = 0.09) in individuals with resectable NSCLCs.Individuals with resectable NSCLCs had significantly higher major pathological response when comparing neoadjuvant chemo-immunotherapy to neoadjuvant chemotherapy, objective response rate to non-objective response rate, and programmed death-ligand 1≥1% to programmed death-ligand 1≤1%, however, no significant difference was found between stage III and stage I-II, and squamous cell cancer and non-squamous cell cancer. To validate this discovery, more research is required since most of the selected studies had a low sample size, and caution must be implemented when interacting with its values.

    Keywords: resectable non-small-cell lung tumors, Prognosis prediction, Pathological response, programmed death-ligand 1, neoadjuvant immunotherapy, stage

    Received: 23 Sep 2024; Accepted: 04 Nov 2024.

    Copyright: © 2024 Nie, Wang, Shi, Zhu, Hao and Tao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Rancen Tao, Department of Oncology, Inner Mongolia Autonomous Region Cancer Hospital, Hohhot, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.